Evidence map›Paper›PMID 33072499›Full record

ArticleActa pharmaceutica Sinica. B2021

Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.

Xiaofei Chen, Yunlong Wu, Chun Chen, Yanqiu Gu, Chunyan Zhu, Suping Wang, Jiayun Chen, Lei Zhang, Lei Lv, Guoqing Zhang and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
29.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Uncovering the covalent inhibitors of SARS-CoV-2 MJournal of pharmaceutical analysis · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Xiaofei ChenSchool of Pharmacy, Naval Medical University, Shanghai 200433, China.
Yunlong WuFujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Chun ChenDepartment of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai 201999, China.
Yanqiu GuDepartment of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai 201999, China.
Chunyan ZhuFujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Suping WangFujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Jiayun ChenFujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Lei ZhangSchool of Pharmacy, Naval Medical University, Shanghai 200433, China.
Lei LvDepartment of Pharmacy, Shanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China.
Guoqing ZhangDepartment of Pharmacy, Shanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China.
Yongfang YuanDepartment of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai 201999, China.
Yifeng ChaiSchool of Pharmacy, Naval Medical University, Shanghai 200433, China.
Mingshe ZhuMassDefect Technologies, Princeton, NJ 08540, USA.
Caisheng WuFujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Second Military Medical University · CNXiamen University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown. Hence, this study aimed to determine human exposure to LHQW components and their anti-COVID-19 pharmacological activities. Analysis of LHQW component profiles in human plasma and urine after repeated therapeutic dosing was conducted using a combination of HRMS and an untargeted data-mining approach, leading to detection of 132 LHQW prototype and metabolite components, which were absorbed

Indexed as

ACE2ACE2, angiotensin-converting enzyme 2AT2, alveolar type IIBiochromatographyComprehensive 2D analysisCOVID-19COVID-19, corona virus disease 2019ddMS2, data dependent tandem mass spectrometry 2DMF, N,N-dimethylformamideDMSO, dimethyl sulfoxideESI, electrospray ionizationGMBS, N-(4-maleimide butyryl oxide)succinimideHPLC, high performance liquid chromatographyHRMS, high resolution mass spectrometryIn vivo exposureLHQW, LianhuaqingwenLianhuaqingwen capsuleMolecular dockingMPTS, mercaptopropyltrimethoxysilaneNMPA, National Medical Products AdministrationPATBSPATBS, precise-and-thorough background-subtractionRAS, renin–angiotensin systemSARS-CoV-2, severe acute respiratory syndrome coronavirus 2SPR, surface plasmon resonanceSurface plasma responseTCM, traditional Chinese medicineTIC, total ion chromatographyTOF/MS, time-of-flight mass spectrometry

Identifiers

PMID33072499
PMCPMC7547831
OpenAlexW3092122033

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.